Psagot Securities Ltd.

Psagot Securities Ltd. is a privately owned investment manager based in Tel Aviv-Yafo, Israel. Established in 1989, the firm specializes in managing equity and fixed income mutual funds, as well as hedge funds for a diverse clientele. It engages in investments across global public equity and fixed income markets while also exploring alternative investment opportunities. The firm conducts in-house research to inform its investment strategies. Psagot Securities operates as a subsidiary of Psagot Investment House Ltd., which is recognized as Israel's largest pension fund manager and has been providing investment management services since its founding in 1963.

Keren Barnea Berger

Vice President, Marketing

Lilach Geva Harel

Senior Deputy to Chief Executive Officer and Head Of Investments

Ofir Naor

Head of Private Investments Group

Shlomo Pasha

Chief Financial Officer and Senior Deputy to Chief Executive Officer

Barak Soreni

Chief Executive Officer

6 past transactions

Veev

Venture Round in 2021
Veev Inc., established in 2017 and based in Minneapolis, Minnesota, is a hybrid real estate solutions company that focuses on transforming the construction and experience of homes. The company offers an innovative home operating system that integrates room-specific lighting, shade, and climate control, while also safeguarding against security threats and cybercrime. Veev employs a panelized building system that utilizes light gauge steel for framing and high-performance acrylic for surfaces, complemented by radiant climate control systems and a digital home ecosystem. Currently, Veev is concentrating on high-performance multifamily units and accessory dwelling units (ADUs), with a development pipeline exceeding 230 units and 620,000 gross building square feet. Their comprehensive approach includes asset management, architectural design, permitting, modular construction, installation, and a digital infrastructure that enhances safety, maintenance, and overall comfort for homeowners.

MeaTech

Venture Round in 2020
MeaTech develops complex cultured meat by combining advanced 3D printing technologies. The company's technology aims to enable the production of meat directly instead of raising the entire animal. The company takes a sample of stem cells from an animal, reproduces these cells, divides them into different meat components, and 3D prints the cultured meat in an accurate shape and structure. They plan to develop clean farming through an industrial cultured meat process without harming animals.

ElectReon

Post in 2020
ElectReon revolutionizes E- mobility with the ultimate goal of eliminating the dependency on oil. It is paving the way for future green e-mobility solutions with a unique “Smart road technology”, by developing a Dynamic Wireless Electrification System for electric transportation. Its technology reduces the need for a large battery in the vehicle and powers it wirelessly via minimal infrastructure located under the driving lane. Eliminating the need to stop for recharging or refueling the vehicle during the day. Once the system has been deployed in the main roads for public transportation then it can serve as a platform for all kind of vehicles eliminating the initial costs. In addition, ElectReon can harvest energy due to vehicle braking and transfer it back to the electricity grid, it reduces the total amount of energy consumed by the transportation sector.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Foresight revolutionizes the ADAS industry by enabling highly accurate and reliable object recognition while ensuring the lowest rates of false alerts.Proven core military technology has been developed, tested and deployed over the past 12 yearsUnique platform that offers ADAS for the Automotive and the Railway industries.Highly experienced management team in the stereo vision technology industry Strong IP and know-how Strategic relationships to solidify position in the market.Focused on the growing semi and fully-automated driving industry.

Blender

Funding Round in 2016
BLender also differentiates itself through DirectMatch, its portfolio creator, and Re-BLend, a secondary trading market within the company. Prosper and LendingClub allow lenders to invest in a variety of loans in small increments to diversify and reduce risk. BLender optimizes this process with its matching algorithm that automatically spreads lenders’ money over a wide variety of loans. With Re-BLend, lenders can buy and sell loans and portfolios among themselves, a service that is not provided by LendingClub and outsourced by Prosper.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.